APO Research
Talk to an analyst

APO RESEARCH · REPORT

General Anxiety Disorder Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global General Anxiety Disorder Therapeutics Market Outlook and Growth Opportunities 2026

26 December 2025191 pages

Choose your research edition.

Industry ResearchGeneral Anxiety Disorder Therapeutics Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal General Anxiety Disorder Therapeutics Industry Growth and Trends Forecast to 203264 pages · $3,450 USDMarket StructureGlobal General Anxiety Disorder Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032178 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal General Anxiety Disorder Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal General Anxiety Disorder Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global General Anxiety Disorder Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for General Anxiety Disorder Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for General Anxiety Disorder Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for General Anxiety Disorder Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the General Anxiety Disorder Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the General Anxiety Disorder Therapeutics market include Bionomics Limited, Edgemont Pharmaceuticals, LLC and H. Lundbeck A/S, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global General Anxiety Disorder Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of General Anxiety Disorder Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents General Anxiety Disorder Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global General Anxiety Disorder Therapeutics market.

General Anxiety Disorder Therapeutics Segment by Company

Bionomics Limited

Edgemont Pharmaceuticals, LLC

H. Lundbeck A/S

General Anxiety Disorder Therapeutics Segment by Type

Itriglumide

Tedatioxetine

EDG-004

Others

General Anxiety Disorder Therapeutics Segment by Application

Clinic

Hospital

Others

General Anxiety Disorder Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global General Anxiety Disorder Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the General Anxiety Disorder Therapeutics key companies, revenue, market share, and recent developments.

3. To split the General Anxiety Disorder Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions General Anxiety Disorder Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify General Anxiety Disorder Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze General Anxiety Disorder Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global General Anxiety Disorder Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of General Anxiety Disorder Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of General Anxiety Disorder Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global General Anxiety Disorder Therapeutics industry.

Chapter 3: Detailed analysis of General Anxiety Disorder Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of General Anxiety Disorder Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of General Anxiety Disorder Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. General Anxiety Disorder Therapeutics Industry Trends Table 2. General Anxiety Disorder Therapeutics Industry Drivers Table 3. General Anxiety Disorder Therapeutics Industry Opportunities and Challenges Table 4. General Anxiety Disorder Therapeutics Industry Restraints Table 5. Global General Anxiety Disorder Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global General Anxiety Disorder Therapeutics Revenue Share by Company (2021-2026) Table 7. Global General Anxiety Disorder Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global General Anxiety Disorder Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global General Anxiety Disorder Therapeutics Company, Product Type & Application Table 10. Global General Anxiety Disorder Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global General Anxiety Disorder Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Itriglumide Table 15. Significant Companies of Tedatioxetine Table 16. Significant Companies of EDG-004 Table 17. Significant Companies of Others Table 18. Global General Anxiety Disorder Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global General Anxiety Disorder Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global General Anxiety Disorder Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global General Anxiety Disorder Therapeutics Sales Value Share by Type (2021-2026) Table 22. Global General Anxiety Disorder Therapeutics Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Clinic Table 24. Significant Companies of Hospital Table 25. Significant Companies of Others Table 26. Global General Anxiety Disorder Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global General Anxiety Disorder Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global General Anxiety Disorder Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global General Anxiety Disorder Therapeutics Sales Value Share by Application (2021-2026) Table 30. Global General Anxiety Disorder Therapeutics Sales Value Share by Application (2027-2032) Table 31. Global General Anxiety Disorder Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global General Anxiety Disorder Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global General Anxiety Disorder Therapeutics Sales Value Share by Region (2021-2026) Table 34. Global General Anxiety Disorder Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global General Anxiety Disorder Therapeutics Sales Value Share by Region (2027-2032) Table 36. Global General Anxiety Disorder Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global General Anxiety Disorder Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global General Anxiety Disorder Therapeutics Sales Value Market Share by Country (2021-2026) Table 39. Global General Anxiety Disorder Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global General Anxiety Disorder Therapeutics Sales Value Market Share by Country (2027-2032) Table 41. Bionomics Limited Company Information Table 42. Bionomics Limited Business Overview Table 43. Bionomics Limited General Anxiety Disorder Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Bionomics Limited General Anxiety Disorder Therapeutics Product Portfolio Table 45. Bionomics Limited Recent Development Table 46. Edgemont Pharmaceuticals, LLC Company Information Table 47. Edgemont Pharmaceuticals, LLC Business Overview Table 48. Edgemont Pharmaceuticals, LLC General Anxiety Disorder Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Edgemont Pharmaceuticals, LLC General Anxiety Disorder Therapeutics Product Portfolio Table 50. Edgemont Pharmaceuticals, LLC Recent Development Table 51. H. Lundbeck A/S Company Information Table 52. H. Lundbeck A/S Business Overview Table 53. H. Lundbeck A/S General Anxiety Disorder Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. H. Lundbeck A/S General Anxiety Disorder Therapeutics Product Portfolio Table 55. H. Lundbeck A/S Recent Development Table 56. Research Programs/Design for This Report Table 57. Authors List of This Report Table 58. Secondary Sources Table 59. Primary Sources List of Figures Figure 1. General Anxiety Disorder Therapeutics Product Image Figure 2. Global General Anxiety Disorder Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global General Anxiety Disorder Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global General Anxiety Disorder Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Itriglumide Image Figure 8. Tedatioxetine Image Figure 9. EDG-004 Image Figure 10. Others Image Figure 11. Global General Anxiety Disorder Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global General Anxiety Disorder Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global General Anxiety Disorder Therapeutics Sales Value Share by Type (2021-2032) Figure 14. Clinic Image Figure 15. Hospital Image Figure 16. Others Image Figure 17. Global General Anxiety Disorder Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global General Anxiety Disorder Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global General Anxiety Disorder Therapeutics Sales Value Share by Application (2021-2032) Figure 20. Global General Anxiety Disorder Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global General Anxiety Disorder Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America General Anxiety Disorder Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. North America General Anxiety Disorder Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe General Anxiety Disorder Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Europe General Anxiety Disorder Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific General Anxiety Disorder Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific General Anxiety Disorder Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America General Anxiety Disorder Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. South America General Anxiety Disorder Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa General Anxiety Disorder Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa General Anxiety Disorder Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Itriglumide
  • Tedatioxetine
  • EDG-004
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Bionomics Limited
  • Edgemont Pharmaceuticals, LLC
  • H. Lundbeck A/S

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global General Anxiety Disorder Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global General Anxiety Disorder Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 General Anxiety Disorder Therapeutics Market Dynamics
  1. 2.1 General Anxiety Disorder Therapeutics Industry Trends
  2. 2.2 General Anxiety Disorder Therapeutics Industry Drivers
  3. 2.3 General Anxiety Disorder Therapeutics Industry Opportunities and Challenges
  4. 2.4 General Anxiety Disorder Therapeutics Industry Restraints
3 General Anxiety Disorder Therapeutics Market by Company
  1. 3.1 Global General Anxiety Disorder Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global General Anxiety Disorder Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global General Anxiety Disorder Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global General Anxiety Disorder Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global General Anxiety Disorder Therapeutics Company Product Type and Application
  6. 3.6 Global General Anxiety Disorder Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global General Anxiety Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 General Anxiety Disorder Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 General Anxiety Disorder Therapeutics Market by Type
  1. 4.1 General Anxiety Disorder Therapeutics Type Introduction
  2. 4.1.1 Itriglumide
  3. 4.1.2 Tedatioxetine
  4. 4.1.3 EDG-004
  5. 4.1.4 Others
  6. 4.2 Global General Anxiety Disorder Therapeutics Sales Value by Type
  7. 4.2.1 Global General Anxiety Disorder Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global General Anxiety Disorder Therapeutics Sales Value by Type (2021-2032)
  9. 4.2.3 Global General Anxiety Disorder Therapeutics Sales Value Share by Type (2021-2032)
5 General Anxiety Disorder Therapeutics Market by Application
  1. 5.1 General Anxiety Disorder Therapeutics Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global General Anxiety Disorder Therapeutics Sales Value by Application
  6. 5.2.1 Global General Anxiety Disorder Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global General Anxiety Disorder Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global General Anxiety Disorder Therapeutics Sales Value Share by Application (2021-2032)
6 General Anxiety Disorder Therapeutics Regional Value Analysis
  1. 6.1 Global General Anxiety Disorder Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global General Anxiety Disorder Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global General Anxiety Disorder Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global General Anxiety Disorder Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America General Anxiety Disorder Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America General Anxiety Disorder Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe General Anxiety Disorder Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe General Anxiety Disorder Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific General Anxiety Disorder Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific General Anxiety Disorder Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America General Anxiety Disorder Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America General Anxiety Disorder Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa General Anxiety Disorder Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa General Anxiety Disorder Therapeutics Sales Value Share by Country, 2025 VS 2032
7 General Anxiety Disorder Therapeutics Country-level Value Analysis
  1. 7.1 Global General Anxiety Disorder Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global General Anxiety Disorder Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global General Anxiety Disorder Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global General Anxiety Disorder Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt General Anxiety Disorder Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt General Anxiety Disorder Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt General Anxiety Disorder Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bionomics Limited
  2. 8.1.1 Bionomics Limited Company Information
  3. 8.1.2 Bionomics Limited Business Overview
  4. 8.1.3 Bionomics Limited General Anxiety Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bionomics Limited General Anxiety Disorder Therapeutics Product Portfolio
  6. 8.1.5 Bionomics Limited Recent Developments
  7. 8.2 Edgemont Pharmaceuticals, LLC
  8. 8.2.1 Edgemont Pharmaceuticals, LLC Company Information
  9. 8.2.2 Edgemont Pharmaceuticals, LLC Business Overview
  10. 8.2.3 Edgemont Pharmaceuticals, LLC General Anxiety Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Edgemont Pharmaceuticals, LLC General Anxiety Disorder Therapeutics Product Portfolio
  12. 8.2.5 Edgemont Pharmaceuticals, LLC Recent Developments
  13. 8.3 H. Lundbeck A/S
  14. 8.3.1 H. Lundbeck A/S Company Information
  15. 8.3.2 H. Lundbeck A/S Business Overview
  16. 8.3.3 H. Lundbeck A/S General Anxiety Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 H. Lundbeck A/S General Anxiety Disorder Therapeutics Product Portfolio
  18. 8.3.5 H. Lundbeck A/S Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst